参考文献/References:
[1] Collaborators G2N.Global, regional, and National burden of neurological disorders, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016[J].Lancet Neurol,2019,18(5):459-480.
[2] Dorsey ER,Bloem BR.The Parkinson pandemic-A call to action[J].JAMA Neurol,2018,75(1):9-10.
[3] Kaur R,Mehan S,Singh S.Understanding multifactorial architecture of Parkinson's disease: pathophysiology to management[J].Neurol Sci,2019,40(1):13-23.
[4] Fayyad M,Salim S,Majbour N,et al.Parkinson's disease biomarkers based on α-synuclein[J].J Neurochem,2019,150(5):626-636.
[5] Du TT,Wang L,Liu WJ,et al.Biomarkers and the role of α-Synuclein in Parkinson's disease[J].Front Aging Neurosci,2021,13:645996.
[6] Tolosa E,Garrido A,Scholz SW,et al.Challenges in the diagnosis of Parkinson's disease[J].The Lancet Neurology,2021,20(5):385-397.
[7] Marinus J,Zhu KD,Marras C,et al.Risk factors for non-motor symptoms in Parkinson's disease[J].Lancet Neurol,2018,17(6):559-568.
[8] Delamarre A,Meissner WG.Epidemiology, environmental risk factors and genetics of Parkinson's disease[J].Presse Med,2017,46(2 Pt 1):175-181.
[9] Fereshtehnejad SM,Zeighami Y,Dagher A,et al.Clinical criteria for subtyping Parkinson's disease: biomarkers and longitudinal progression[J].Brain,2017,140(7):1959-1976.
[10] Becker G,Seufert J,Bogdahn U,et al.Degeneration of substantia nigra in chronic Parkinson's disease visualized by transcranial color-coded real-time sonography[J].Neurology,1995,45(1):182-184.
[11] Bor-Seng-Shu E,Paschoal FM,Almeida KJ,et al.Transcranial brain sonography for Parkinsonian syndromes[J].J Neurosurg Sci,2019,63(4):441-449.
[12] Richter D,Woitalla D,Muhlack S,et al.Brainstem raphe alterations in TCS: a biomarker for depression and apathy in Parkinson's disease patients[J].Front Neurol,2018,9:645.
[13] Jiang H,Wang J,Rogers J,et al.Brain Iron metabolism dysfunction in Parkinson's disease[J].Mol Neurobiol,2017,54(4):3078-3101.
[14] 刘军.中国帕金森病的诊断标准(2016版)[J].中华神经科杂志,2016,49(4):268-271.
[15] Prati P,Bignamini A,Coppo L,et al.The measuring of substantia nigra hyperechogenicity in an Italian cohort of Parkinson disease patients: a case/control study(NOBIS Study)[J].J Neural Transm(Vienna),2017,124(7):869-879.
[16] Behnke S,Berg D,Naumann M,et al.Differentiation of Parkinson's disease and atypical parkinsonian syndromes by transcranial ultrasound[J].J Neurol Neurosurg Psychiatry,2005,76(3):423-425.
[17] Richter D,Katsanos AH,Schroeder C,et al.Lentiform nucleus hyperechogenicity in Parkinsonian syndromes: a systematic review and meta-analysis with consideration of molecular pathology[J].Cells,2019,9(1):2.
[18] Scherfler C,Schwarz J,Antonini A,et al.Role of DAT-SPECT in the diagnostic work up of Parkinsonism[J].Movement disorders,2007,22(9):1229-1238.
[19] Akdemir UO,Bora TA,Atay LO.Dopamine transporter SPECT imaging in Parkinson's disease and Parkinsonian disorders[J].Turkish Journal Of Medical Sciences,2021,51(2):400-410.
[20] Meles SK,Oertel WH,Leenders KL.Circuit imaging biomarkers in preclinical and prodromal Parkinson's disease[J].Mol Med,2021,27(1):111.
[21] Liu FT,Ge JJ,Wu JJ,et al.Clinical, dopaminergic, and metabolic correlations in Parkinson disease: a dual-tracer PET study[J].Clin Nucl Med,2018,43(8):562-571.
[22] Orimo S,Suzuki M,Inaba A,et al.123I-MIBG myocardial scintigraphy for differentiating Parkinson's disease from other neurodegenerative parkinsonism: a systematic review and meta-analysis[J].Parkinsonism Relat Disord,2012,18(5):494-500.
[23] Katzenschlager R,Lees AJ.Olfaction and Parkinson's syndromes: its role in differential diagnosis[J].Curr Opin Neurol,2004,17(4):417-423.
[24] Postuma RB,Poewe W,Litvan I,et al.Validation of the MDS clinical diagnostic criteria for Parkinson's disease[J].Mov Disord,2018,33(10):1601-1608.
[25] Blauwendraat C,Nalls MA,Singleton AB.The genetic architecture of Parkinson's disease[J].The Lancet Neurology,2020,19(2):170-178.
[26] Nalls MA,Blauwendraat C,Vallerga CL,et al.Identification of novel risk loci, causal insights, and heritable risk for Parkinson's disease: a meta-analysis of genome-wide association studies[J].Lancet Neurol,2019,18(12):1091-1102.
[27] Parnetti L,Gaetani L,Eusebi P,et al.CSF and blood biomarkers for Parkinson's disease[J].The Lancet Neurology,2019,18(6):573-586.
[28] Donadio V,Incensi A,Leta V,et al.Skin nerve α-synuclein deposits: a biomarker for idiopathic Parkinson disease[J].Neurology,2014,82(15):1362-1369.
[29] Tsukita K,Sakamaki-Tsukita H,Tanaka KT,et al.Value of in vivo α-synuclein deposits in Parkinson's disease: a systematic review and meta-analysis[J].Movement Disorders,2019,34(10):1452-1463.
[30] Vilas D,Iranzo A,Tolosa E,et al.Assessment of α-synuclein in submandibular glands of patients with idiopathic rapid-eye-movement sleep behaviour disorder: a case-control study[J].Lancet Neurol,2016,15(7):708-718.
[31] Wang ZR,Becker K,Donadio V,et al.Skin α-Synuclein aggregation seeding activity as a novel biomarker for Parkinson disease[J].JAMA Neurol,2020,78(1):1-11.
[32] Rossi M,Candelise N,Baiardi S,et al.Ultrasensitive RT-QuIC assay with high sensitivity and specificity for Lewy body-associated synucleinopathies[J].Acta Neuropathol,2020,140(1):49-62.
[33] van Rumund A,Green AJE,Fairfoul G,et al.α-Synuclein real-time quaking-induced conversion in the cerebrospinal fluid of uncertain cases of Parkinsonism[J].Ann Neurol,2019,85(5):777-781.
[34] Zucca FA,Capucciati A,Bellei C,et al.Neuromelanins in brain aging and Parkinson's disease: synthesis, structure, neuroinflammatory, and neurodegenerative role[J].IUBMB Life,2023,75(1):55-65.
[35] Sasaki M,Shibata E,Tohyama K,et al.Neuromelanin magnetic resonance imaging of locus ceruleus and substantia nigra in Parkinson's disease[J].Neuroreport,2006,17(11):1215-1218.
[36] Wang XM,Zhang YH,Zhu C,et al.The diagnostic value of SNpc using NM-MRI in Parkinson's disease: meta-analysis[J].Neurol Sci,2019,40(12):2479-2489.
[37] Chen Q,Chen Y,Zhang Y,et al.Iron deposition in Parkinson's disease by quantitative susceptibility mapping[J].BMC Neurosci,2019:23.
[38] An HD,Zeng XY,Niu TF,et al.Quantifying Iron deposition within the substantia nigra of Parkinson's disease by quantitative susceptibility mapping[J].J Neurol Sci,2018,386:46-52.
[39] Thomas GEC,Leyland LA,Schrag AE,et al.Brain Iron deposition is linked with cognitive severity in Parkinson's disease[J].J Neurol Neurosurg Psychiatry,2020,91(4):418-425.
[40] Li DTH,Hui ES,Chan Q,et al.Quantitative susceptibility mapping as an indicator of subcortical and limbic Iron abnormality in Parkinson's disease with dementia[J].Neuroimage Clin,2018,20:365-373.
[41] Helmich RC,Vaillancourt DE,Brooks DJ.The future of brain imaging in Parkinson's disease[J].J Parkinsons Dis,2018,8(s1):S47-S51.
[42] Saeed U,Lang AE,Masellis M.Neuroimaging advances in Parkinson's disease and atypical Parkinsonian syndromes[J].Front Neurol,2020:572976.
[43] Espay AJ,Bonato P,Nahab FB,et al.Technology in Parkinson's disease: challenges and opportunities[J].Mov Disord,2016,31(9):1272-1282.
[44] Lu RR,Xu Y,Li XH,et al.Evaluation of wearable sensor devices in Parkinson's disease: a review of current status and future prospects[J].Parkinsons Dis,2020,2020:4693019.
[45] Rehman RZU,Klocke P,Hryniv S,et al.Turning detection during gait: algorithm validation and influence of sensor location and turning characteristics in the classification of Parkinson's disease[J].Sensors(Basel),2020,20(18):5377.